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can help to understand common underlying pathways, and the use of drugs targeted 
to associated symptoms.
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Objectives: To quantify men’s preferences and willingness to pay for attributes 
of medications to treat LUTS/BPH using a DCE. MethOds: An online DCE was 
conducted with men in the UK aged ≥ 45 years with a self-reported International 
Prostate Symptom Score (IPSS) ≥ 8. Men were asked to consider different scenarios 
associated with moderate-to-severe LUTS, and then choose between two medical 
alternatives and a no-treatment option, according to seven attributes: day-time 
urinary frequency, night-time urinary frequency, urgency, sexual and non-sexual 
side effects, number of tablets/day and cost/month. These attributes were identi-
fied from a literature review and online discussion groups (ODGs). Men’s marginal 
willingness to pay (MWTP) and 95% confidence intervals for improvements in each 
attribute were calculated. Please see a separate meeting abstract for more informa-
tion on the ODGs (Ikenwilo, et al). Results: The DCE survey was conducted 19–26 
March 2014. 5212 individuals were invited to participate: 1097 opened the hyperlink, 
586 were ineligible or excluded because the quota was full, and 247 completed the 
final survey used for this analysis. The mean age was 62.3 years and the mean IPSS 
was 15.7 (standard deviation 6.0). MWTP was £23.95/month and £25.42/month for 
an improvement from urge incontinence to moderate urgency or mild urgency, 
respectively; £5.80/month for one less night-time urination, and £1.30/month for 
one less day-time urination. Sexual side effects reduced MWTP by £29.70/month 
for erectile dysfunction, £18.37/month for “decreased sexual desire”, and £16.92/
month for “no fluid during ejaculation”. Non-sexual side effects reduced MWTP by 
£17.25/month for dizziness and £16.75/month for headaches. Neither dry mouth nor 
the number of tablets/day significantly affected MWTP.cOnclusiOns: Improving 
urgency is perceived as the most important benefit of medication to men with LUTS/
BPH; improving frequency is also valued. The perceived value of a medication is 
reduced by sexual and non-sexual side effects. 
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Objectives: “Off-label” is defined by the Turkish Ministry of Health (MoH) as 
the use of licensed pharmaceutical products in doses outside the scope of the 
registered indication and the use of unlicensed medicinal products that are 
imported for the purpose of individual treatment. Off-label use of medications is 
extremely common especially in oncology. The aim of the study is to evaluate the 
usage of off-label or unlicensed medicines in urologic cancers for understand-
ing of Turkey’s perspective within this area of health care provisions. MethOds: 
This study involved patients (n= 105) with metastatic bladder CA who received 
paklitaxel or other medicine application off-label, (n= 194) with metastatic renal 
cell CA who received sorafenib, sunitinib or other medicine application off-label, 
(n= 44) with metastatic testis cancer who received paklitaxel, gemsitabin or other 
medicine application off-label in Turkey. A computer search was performed using 
the TITCK’s (Turkish Drug and Medical Devices Institution) database. The patient 
base was searched for off-label medicine applications between 1st May 2008 to 
1st May 2011. Results: The data obtained from TITCK’s database showed that 86, 
136, and 44 applications for off-label metastatic bladder CA medicine, metastatic 
renal cell CA and metastatic testis CA medicine usage, respectively. Ninety five 
(90.47%) of all off-label medicine usage applications for metastatic bladder CA, one 
hundred twenty two (62.88%) for metastatic renal cell CA and thirty nine (88.63%) 
for metastatic testis CA were approved. University hospitals were created the vast 
majority of applications (79.89%) for metastatic bladder CA, (64.76%) for metastatic 
bladder CA and (79.89%) for metastatic bladder CA. The most preferable off-label 
drug medications for bladder CA, renal CA and testis CA were paklitaksel (84.04%), 
sorafenib (68.42%) and paklitaksel (43.24%), respectively. cOnclusiOns: Off-label 
urology medicine use is rising in Turkey. If off-label use increasing parallel to the 
off-label urology medicines, it is needed to define new pathways to evaluate the 
applications.
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Objectives: To assess health-related quality of life (HRQOL) and subjective happiness 
of men with lower urinary tract symptoms associated with benign prostatic hyper-
plasia (BPH/LUTS). MethOds: In 2014 a multicenter cross-sectional questionnaire 
survey was conducted in Hungary. Inclusion criteria were diagnosis of BPH/LUTS at 
least 12 months before the study and patient had never been undergone any prostate 
surgery. HRQOL was assessed indirectly by the EQ-5D and visual analogue scale (EQ 
VAS) and directly by matching indifference time trade-off (TTO) where patients’ sub-
jective life expectancy was applied as time frame. Subjective happiness was measured 
on a 10-cm-long visual analogue scale. Results: In total 64 men completed the 
questionnaire, mean age and disease duration were 70.8±8.8 years and 6.9±6.5 years, 
respectively. At the time of the survey, 75% of the patients received alpha-blockers 
(AB), 11% were treated by 5-alpha-reductase inhibitors (5ARI), and 11% by combina-
tion therapy (AB+5ARI). Median EQ-5D, EQ VAS, TTO and happiness scores were 0.85, 
70, 0.73 and 6.5, respectively. Utilities assessed by EQ-5D were found significantly 
higher compared to those elicited by TTO (p< 0.001). Mean utilities decreased with 
clinical severity measured with EQ-5D (mild: 0.90±0.1, moderate to severe: 0.79±0.2, 
p= 0.046) whereas increased when assessed with TTO (mild: 0.46±0.3, moderate to 
severe: 0.63±0.3, p= 0.336). Patients with moderate to severe disease reported signifi-
cantly lower happiness scores than those with mild disease (5.85±2.2 and 7.02±2.3, 
p= 0.044). Subjective happiness correlated moderately with EQ VAS (rs= 0.64, p< 0.001) 
but only weakly with EQ-5D (rs= 0.28, p= 0.029). cOnclusiOns: BPH/LUTS patients 
experience notable reduction in their HRQOL and subjective happiness measured by 
any of the applied outcome measures. Utilities for BPH/LUTS ranged from 0.46 to 0.90 
depending on clinical severity and assessment method. Considerable discrepancy was 
found between utilities elicited by EQ-5D and TTO that raises concerns about which 
method is feasible to use for utility evaluation in BPH/LUTS.
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Objectives: To understand men’s attitudes, preferences and values for LUTS/BPH 
management and its impact on quality of life (QoL) using a MMA. MethOds: The 
innovative MMA approach combined qualitative (online discussion groups [ODG]) 
and quantitative methods (discrete choice experiment [DCE]). ODGs and a self-
administered online DCE survey were conducted with men in the UK aged ≥ 45 
years with an International Prostate Symptom Score (IPSS) ≥ 8. A series of five asyn-
chronous ODGs (or bulletin boards) were live for 5 days (moderated by the research 
team). The ODGs collected information about men’s experiences of LUTS/BPH and 
its impact on their QoL; data were analysed using an inductive thematic analysis. 
A literature review informed the ODG design, and both informed the DCE design. 
The DCE survey elicited men’s preferences for LUTS/BPH medical management. 
Please see a separate meeting abstract for more information on the DCE (Ikenwilo, 
et al). Results: 48 men were invited to the ODGs; 22 participated and had a mean 
age of 59.8 years and mean IPSS of 16.4 (standard deviation 7.1). The ODGs found that 
LUTS/BPH affects how men organise their day at work and at home, and prevents 
men from leading their preferred daily activities. Symptoms most adversely affect-
ing QoL were urgency (especially urge incontinence) and day-time and night-time 
urinary frequency. There appears to be a lack of awareness about LUTS amongst 
the men: many had not discussed LUTS with their doctor, family or friends, and 
were unaware that LUTS/BPH is treatable. The DCE informs that men are willing to 
pay at least £23.95/month to improve urgency, and £29.70/month to avoid erectile 
dysfunction. cOnclusiOns: This is the first MMA to evaluate men’s preferences in 
LUTS/BPH. The ODG and DCE results together expand our understanding of men’s 
attitudes toward the management of LUTS/BPH.
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Objectives: This study assessed the prevalence of symptoms, and symptom clusters 
in a sample of dialysis patients in Uruguay. MethOds: A longitudinal study aimed 
to assess HRQL in hemo (HD) and peritoneal dialysis patients (PD) was conducted 
in thirteen centers in Uruguay. Data of the first assessment was included here. The 
12 items of the KDQOL-36 Symptom Subscale were analyzed for symptom preva-
lence. For cluster analyses the ICLUST procedure was followed, using an algorithm 
to hierarchically cluster items to form composite scales. Alpha, the mean split half 
correlation, and beta, the worst split half correlation, are estimates of the reliabil-
ity and general factor saturation of the test. Clusters are combined if coefficients 
increase in the new cluster. Results: Of a total of 751 patients, 486 accepted to 
participate and completed the forms (64.7%), with mean age 60.5 years, SD: 15.5), 
211 (43.4%) were women; 407 (83.7%) were HD, and 79 (16.3%) were PD patients. 
Most prevalent symptoms were muscle sores (59.0%); cramps (57.5%); “washed out” 
(50.9%), dry skin (48.5%), and itchy skin (43.8%). Five clusters of symptoms were 
identified; “cutaneous” (itchy and dry skin, α  .68), ”cardiac” (chest pain and short-
ness of breath, α  .69), ”digestive” (nausea and lack of appetite, α .62), ”neurophatic” 
(numbness and cramps, α  .50), ”energy” (“washed out”, faintness, α  .59). A second 
block called “locomotive” included neuropathic plus muscle sores (α  .64), and a third 
of “neurological symptoms” included locomotive plus energy (α .70). Cutaneous 
symptoms remained as a separated cluster. Cronbach alpha of the total Symptom 
Scale was .93. cOnclusiOns: Dialysis patients experience a high number of 
symptoms. The study of clusters identified 5 groups of symptoms; cutaneous, cardiac, 
neuropathic, digestive and lack of energy. More complex associations included neu-
rological, digestive and cardiac complaints. The identification of symptom clusters 
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or units (normal ward = 13%, ICU = 15%, catheter laboratory or operating room = 62% 
and other = 10%). The average additional cost of any single complication was € 3,438 
(p< 0.01). Life-threatening non-access site bleeding was associated with the highest 
additional costs (€ 47,494; p< 0.05), followed by stage 3 AKI (€ 20,468; p< 0.01), implanta-
tion of a second valve (€ 16,767; p< 0.01) and other severe cardiac dysrhythmia (€ 10,611 
p< 0.05). Interestingly, censoring cases of in-hospital mortality is associated with a 
substantial decrease in the additional costs. cOnclusiOns: Bleeding complications, 
severe kidney failure, and implantation of a second valve are the most important cost 
drivers in TAVR patients, and strategies to reduce those complications may have the 
potential to generate significant in-hospital cost reductions.
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adverse evenTs (Tes), as recorded in Large heaLTh care daTaBase 
dUring 2008-2013 sTUdy Period
Ekezue B.F.1, Sridhar G.1, Izurieta H.S.2, Forshee R.A.2, Selvam N.1, Ovanesov M.V.2, Jain N.2, 
Mintz P.D.2, Anderson S.A.2, Menis M.2
1HealthCore Inc., Alexandria, VA, USA, 2U. S. Federal Drug Administration, Silver Spring, MD, 
USA
Objectives: There has been an increase in the number of clotting factor (CF) prod-
ucts available in the U. S. in recent years. Thrombotic events (TEs) are serious adverse 
events that can occur following administration of CFs. The objective of this study 
is to assess the same-day TE risk following exposure to CF products. MethOds: 
A retrospective cohort study of individuals exposed to CF products during January 
2008 through June 2013 was conducted using HealthCore Integrated Research Database 
(HIRDSM). CF products were identified by Health care Common Procedure Coding System 
(HCPCS) codes, and TEs were ascertained via ICD-9-CM diagnosis codes. Crude same-
day TE rates (per 1,000 persons exposed) were estimated overall, by congenital clotting 
factor deficiency status and by specific CF products, age, and gender. Results: Of 3,801 
individuals exposed to CFs, 117 (30.8 per 1,000 persons) had TEs recorded on the same-
day as CF exposure. The crude same-day TE rate (per 1,000) was higher for CF users 
without congenital CF deficiency, 70.2 (102 of 1,452), as compared to those with con-
genital CF deficiency, 6.4 (15 of 2,349), unadjusted rate ratio of 11.0 (95% CI 6.4-18.9). For 
individuals without congenital CF deficiency, the crude TE rates (per 1,000) were 15.9 for 
under 15 years of age, 16.1 for 15 to 44 years, 62.8 for 45 to 64 years, and 160.9 for 65 years 
and older. The unadjusted same-day TE rates (per 1,000) ranged from 12.8 for Factor 
VIII to 204.1 for Factor IX complex product(s). Multivariable analyses are underway to 
control for potential confounders and identify recipient risk factors. cOnclusiOns: 
The study shows an increased risk of same-day TEs for CF users without congenital 
CF deficiency and suggests a potentially substantial off-label use of CFs, which needs 
further investigation. In addition, study findings suggest elevated same-day TE rates for 
specific CF products with additional multivariable investigation ongoing.
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Objectives: Acute myocardial infarction (AMI) is a major cause of mortality 
and disability worldwide. AMI occurs when blood flows irregularly into heart and 
thus heart muscle is injured due to insufficient constant oxygen received. It will 
cause severe complications or co-morbidities if the condition is lasting. Hence, 
we hypothesized the atrial fibrillation (AF) is an independent risk factor to the 
major severe cardiovascular events (MACE) after AMI occurred. MethOds: The 
AMI patient is defined by the patient treated in the emergency room at the begin-
ning of the illness. Frequencies and costs of AMI data were extracted from the 
National Health Insurance Research Database for this observational retrospective 
cohort study between 2007 and 2012 in Taiwan. ICD-9-CM 410 was used to extract 
the AMI patients. Fisher’s exact test and categorical data analytic method were 
utilized to assess the AF as a risk factor to MACE in the AMI patients. Results: We 
mainly focused on the AMI adults without any prior MACE occurred. As a result, 
there were 3,452 AMI who can be divided into 2 groups: 2,939 AF patients and 513 
non-AF patients. The average medical cost was USD$ 3142.8 and the mean LoS 
was 10.4 days with st. d. 29.0 days. There were 1,791 MACE identified among the AF 
patients (60.9%), while there were 251 MACE among the non-AF patients (48.9%). 
In consequence, the AMI with AF resulted more MACE than those in non-AF (RR = 
1.63, C.I. = (1.35, 1.97), p < 0.0001). The difference of cost was not significant between 
both groups. The mean LoS in AF was 16.6 days, which was significantly smaller 
than that in non-AF (19.1 days). The difference was probably due to higher fatalities 
in AF. cOnclusiOns: This study has demonstrated that AF risk is associated with 
MACE in patients after AMI occurred.
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bAckgROund: Proactive, post-authorization monitoring of drug safety and effec-
tiveness is of increasing importance. Rivaroxaban is a Factor Xa inhibitor with 
multiple indications, including: treatment of venous thromboembolism (VTE) and 
prevention of recurrent VTE; stroke prevention in atrial fibrillation; and prevention 
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Objectives: Data are limited on the course of patients after an acute venous throm-
boembolism (VTE) event under clinical practice conditions. MethOds: We present 
current data on the re-hospitalization of patients with deep venous thrombosis 
(DVT) or pulmonary embolism (PE) from the PREFER in VTE registry in 7 Western 
European countries (France, Italy, Spain, Germany, UK, Austria and Switzerland). 
The current interim analysis includes data of 2863 patients. 1689 patients had DVT 
alone and 1174 had PE (±DVT) as qualifying event for inclusion. Results: At base-
line, 72.2% of the patients received heparin, 11.9% fondaparinux, 48.0% vitamin K 
antagonists, 25.4% non-VKA oral anticoagulants, 7.0% acetylsalicylic acid, 2.1% other 
antiplatelets and 1.6% thrombolysis agents. Within the first 6 months, 14.7% of VTE 
patients were hospitalized for any reason (DVT: 12.9%, PE: 17.5%). Hospitalization 
rates varied between countries (Spain 10.7%, Germany 10.8%, France 12.5%, Italy 
19.3%, UK (at 3 months) 7.5%). The mean number of hospitalizations was 1.3 ±0.85 
(1.1 to 1.5 in the various countries; median 1, range 1-6). The documented reasons for 
hospitalization, among others, were VTE (15.3%), surgery/trauma (13.5%), bleeding 
(7.4%), or stroke/TIA (3.7%). Mean duration of all combined hospital stays was 9.8 
±12.61 days (4.0 days in Germany,  4.7 in France, 9.0 in Spain, 14.0 in Italy). The overall 
median duration of hospitalization was 6 days (interquartile range 2-12), for DVT 
cases it was 6 days (IQR 3-13), for PE cases it was 5 days (IQR 2-11). cOnclusiOns: 
Under real-life conditions, one in seven patients had to be readmitted to hospital 
in the first 6 months after the DVT or PE event. However, the majority of hospitali-
zations were not due to the thromboembolic disease or bleeding. The duration of 
hospital stays showed a wide range across Western European countries.
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Objectives: The great majority of patients with atrial fibrillation (AF) require life-
long antithrombotic therapy for prevention of stroke. For optimal treatment, it is 
important to investigate treatment discontinuations, as those might be associated 
with increased hospitalization rates. As potential indicator for unstable anticoagula-
tion efforts we assessed hospitalization rates for non-vitamin K antagonist oral anti-
coagulants (NOAC) and for warfarin under real-life practice conditions. MethOds: 
PREFER in AF (The PREvention oF thromboembolic events – European Registry in 
Atrial Fibrillation) is a prospective non-interventional disease registry of patients 
with AF in 7 countries in Western Europe. Discontinuation rates were assessed look-
ing at all patients (n= 6412), whereas hospitalization rates reported at Baseline (BL) 
and 1 year Follow-Up (FU) focused on two groups: patients treated with warfarin 
(BL= 1379, FU= 1571) and patients treated with NOAC (BL= 194, FU= 424). Descriptive 
statistics were applied. Results: Out of 6412 patients, 9 to 18% of patients treated 
with vitamin K antagonists (VKA) discontinued therapy (warfarin 10.3%, phenpro-
coumon 9%, acenocoumarol 10.4%, fluinidone 18%). The discontinuation rates for 
patients on NOAC were 9.4% for rivaroxaban and 10.3% for dabigatran, respectively. 
Reported hospitalization rates (irrespective of reason) were 19.8%/10.0% for NOAC, 
and 24.1%/11.6% for warfarin at BL or FU, respectively. Mean duration of hospitali-
zation was 1.3±4.0/ 0.9 ±5.1 days for NOAC, and 2.0±6.1/ 1.0 ±4.2 days for warfarin.  
cOnclusiOns: No major differences were observed in the discontinuation rates 
between VKA and NOAC on the class level nor the various available NOAC drugs. 
Hospitalization rates and corresponding number of days in hospital reported at BL 
were substantially higher compared to FU. Patients on NOAC had lower hospitaliza-
tion rates and less days in hospital compared to those on warfarin. Further analyses 
are needed to explore the reasons for hospitalizations.
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Objectives: Transcatheter aortic valve replacement (TAVR) is a relatively new 
alternative to surgical replacement of the aortic valve. Recent development of third 
generation systems and new products have shown reductions in the frequency and 
severity of complications associated with the procedure. The aim of this study was 
to identify the cost impact of complications for patients undergoing TAVR in a German 
hospital. MethOds: Data was derived from a prospective observational study, 
whereby a total of 163 consecutive patients were treated either with transfemoral 
(TF-, n= 97) or transapical (TA-) TAVR (n= 66) between February 2009 and December 
2012. Predefined clinical endpoints were analyzed, “in-hospital” costs determined 
from the hospital perspective (2012= 100) and results reported within the seven most 
relevant cost categories. Results: TF-TAVR patients experienced more minor access 
site bleeding (p= 0.017), major non-access site bleedings (p= 0.026), minor vascular 
complications (p= 0.002), stage 2 acute kidney injury (AKI, p= 0.043) and permanent 
pacemaker implantation (p< 0.001) compared with TA-TAVR. However, total in-hos-
pital costs did not differ between groups (mean € 40,348; SD € 15,851). Costs were pro-
portioned in either categories (staff = 26%, materials = 62% and infrastructure = 12%) 
